NYTech
People
Personfounder

Ariel Katz

Ariel Katz is a co-founder and chief executive of H1, a New York-based company that has built what he describes as one of the largest data platforms cataloguing healthcare professionals, positioning it as a way to connect doctors, patients, and pharmaceutical companies across a fragmented healthcare system [1][2][10]. Katz has framed H1's mission as creating "a healthier future" by serving as a source of truth for physician information, and he has said the company's long-term goal is to facilitate around 100 million patient-doctor interactions and to have half of U.S. clinical trials use H1 to recruit diverse patients and investigators [11]. He traces the company's technical ambitions to natural-language search capabilities that would let a person locate the best-rated doctor for a specific condition in a given city, a feature he says does not yet fully exist but that H1 is building through investment in data science and engineering [10][11].

Katz's path to H1 began with an earlier venture, Research Connection, which he started as a college student after struggling to find research opportunities at his own university despite doing neuroscience research at Columbia's consciousness lab [11][12]. That company, which he described as functioning like a job board for academic research, grew to serve hundreds of thousands of student users after Katz raised roughly $500,000 to $600,000 largely through cold emails, before the founders sold the company after concluding they lacked the traction to raise a Series A round [12]. After Research Connection's sale, Katz spent time away from work before meeting his eventual H1 co-founder through a mutual contact and pitching him the idea that became H1 [12].

Katz has described H1's growth as unusually rapid, noting that the company joined Y Combinator in 2020 despite already having several million dollars in revenue, after a YC partner persuaded him the accelerator could help the company secure better terms than a venture term sheet it had already signed [10]. He recounts that H1 subsequently raised close to $200 million across funding rounds, including roughly $58 million in 2020 and further rounds totaling over $120 million in 2021 and early 2022, guided by an investor argument that more capital lets a company test more "cards on the table" to find what drives growth [10]. He has said that a chief-executive's role shifts over a company's life, from finding product-market fit to later getting the product in front of as many people as possible without breaking the company [11].

In discussing healthcare technology trends, Katz has argued that artificial intelligence's biggest near-term impact on clinical trials lies not in drug discovery but in reducing administrative overhead, such as selecting the right investigators, research sites, and patient populations, and informing trial protocol design [9]. He has also linked pricing policies such as most-favored-nation drug pricing and the Inflation Reduction Act to shifts in where pharmaceutical companies choose to run trials globally, suggesting that companies may curtail trials or drug launches in some countries as U.S. prices are pushed toward international averages [9]. Katz recommends that companies adopt structured evaluation frameworks for assessing new AI tools and has said that firms which delay adoption risk falling behind competitors [9].

Founded

Insights & ideas

Ariel Katz argues that the most valuable application of AI in clinical trials is not in flashy drug discovery but in reducing operational and administrative overhead, such as selecting the right doctors and research sites, locating patients, and informing protocol design [2]. He believes the pharmaceutical industry has moved past a phase of cautious experimentation with AI, warning that companies which continue to merely watch and wait risk falling behind competitors who are already adopting these tools [2].

Katz also connects policy shifts, particularly Most Favored Nation drug pricing and the Inflation Reduction Act, to concrete changes in how and where clinical trials are conducted globally, suggesting that MFN pricing could lead pharma companies to withhold drugs or trials from certain countries rather than lower prices, while the IRA is pushing companies toward concurrent multi-indication studies [2]. On a personal level, he credits an intense thirteen-year K-12 experience at a demanding Jewish prep school with building the resilience that later fueled his entrepreneurial drive, including founding a research-matching platform in college before starting H1 [1].

Experience

  1. CEO & Co-founder
    H1Nov 2018 to Present
  2. CEO and Co-Founder (Acquired)
    ResearchConnectionMay 2013 to Nov 2016
  3. Research Assistant
    Columbia UniversityJun 2013 to Aug 2013

Education

Media & appearances

This page shows public professional information only, each fact cited. Is this you? Corrections or removal within 24 hours, no questions asked.